The Merger of Cerba Research and Viroclinics-DDL
Together, transforming diagnostics for clinical trials
After the acquisition of Viroclinics-DDL by the group Cerba Healthcare, we are delighted to announce that Cerba Research, the group’s global clinical trial central and speciality laboratory services division, has now merged with Viroclinics-DDL, a fast-growing global specialist virology and immunology contract research organisation (CRO).
We are united in our shared expertise, values, and mission for improving people’s lives by enabling clinical trials for drug development across the world. Our ambition is to build the future of healthcare together with our people and customers.
Expanding and transforming our diagnostic solutions for clinical trials while reducing risk for our customers
With our enhanced portfolio of integrated specialty testing services and assay development in multiple therapeutic areas, and the latest technology available in flow cytometry, immunohistochemistry, NGS, and immunoassay, we offer a more comprehensive portfolio of solutions and capabilities at every stage of clinical trials.
Our portfolio of scientific and technical expertise combined with our global capabilities, vast databases of patient data and samples, and best-in-class logistics remove the uncertainty from sample management, reduce risk, and enable the accuracy and acceleration of your drug development projects from start to finish.
Access to exceptional scientific and technical teams in multiple treatment areas for drug and vaccine development
With our unparalleled scientific expertise, the fast-expanding portfolio of therapeutic areas includes a focus on Oncology and Immuno-Oncology, Metabolic Diseases, Virology and other Infectious Diseases, Inflammatory and Autoimmune Diseases, Neurology and Rare Diseases.
Your global partner for specialised laboratories and patient data
Our customers will continue to access industry-leading scientists and technical teams with our cutting-edge specialist laboratory network of over 1000 labs including, BSL2 and BSL3 labs in Europe, the Americas, Africa, Asia and Australia, as well as data from over 45 million patients across five continents, removing the uncertainty from accessing patient data.
Best-in-class logistics services
This merger makes secure sample management and transportation at a global scale even more effective. Our global in-house logistics capability will facilitate a safe and guaranteed sample management process, ensuring that even the most fragile and unstable samples are transported without compromising their integrity and safety. Every sample counts.
Business as usual
Both Cerba Research and Viroclinics-DDL take pride in their project management and customer service capabilities and skills. Now, as one company, our customer-centric approaches are strengthened even more. For our customers, there will be no disruptions. It is business as usual. Both companies will eventually unite under the Cerba Research brand, however over the coming weeks, Viroclinics DDL will be known as a Cerba Research company, reflected in the updated logo.
Cerba Healthcare Enters Agreement to Acquire Viroclinics-DDL
CERBA HEALTHCARE ENTERS AGREEMENT TO ACQUIRE VIROCLINICS-DDL EXPANDING AND TRANSFORMING ITS OFFERING IN CLINICAL TRIALS
- The acquisition illustrates the Group’s strategy to strengthen its position in the entire value chain of diagnosis and stresses the pivotal role of clinical trial services.
- It offers Viroclinics-DDL a broader range of capabilities in its specialty services, and a unique entry into new markets in North America, Asia, and Africa.
Issy Les Moulineaux, France and Rotterdam, The Netherlands, 16 December 2021 – Cerba HealthCare, a leading global player in medical diagnosis, today announced it has reached agreement to acquire Viroclinics-DDL, a fast-growing global virology and immunology con-tract research organization (CRO) from Summit Partners.
Viroclinics-DDL, employing a total of over 390 scientists and experts, offers a broad range of virology related services in the field of non-clinical and clinical trials, clinical diagnostics, assay development and clinical trial logistics enabling the development of antiviral drugs, vaccines, and other therapies. The acquisition fits perfectly into CerbaHealthCare’s strategy aimed at further strengthening its position in the entire diagnostic and clinical trial laboratory services value chain, while providing the most relevant services to patients, the medical community and healthcare industry players. Within the Cerba Research division, Viroclinics-DDL will be able to further broaden its services and access new markets in North America, Asia, and Africa.
Based in the Netherlands, Viroclinics-DDL brings the best scientific expertise in virology, with core competencies across the entire drug development process, from the preclinical phase to market approval, with unique virology assay capabilities and unparalleled experience working with highly pathogenic viruses. With its global network of 38 processing labs, Viroclinics-DDL is able to support large multinational clinical trials. Its strong logistics infrastructure is critical for the swift and safe transport of fragile virology and PBMC (Peripheral Blood Mononuclear Cell) samples from the patient to the lab.
Alongside its historical activities in routine and specialty clinical pathology with sound positions in Europe and Africa, Cerba HealthCare also has a worldwide presence through its expertise in clinical pathology for clinical trials, showcasing the Group’s geographic and expertise diversification to sustain its integrated vision for diagnosis.
Within CerbaHealthCare’s comprehensive Group offering, and ranking under the Cerba Research brand, clinical laboratory and diagnostic solutions for clinical trials have grown considerably over the past years, demonstrating a strong track record in patient recruitment and clinical trial sample testing, as well as in logistics solutions for immuno-oncology, anti-infectives and metabolic disorders. Over the years, Cerba Research has evolved to be the precision medicine partner to CROs, the biotechnology and pharmaceutical industry, and non-profit organizations with growing needs for complex clinical research programs.
Cerba Research CEO Mario Papillon said: “The acquisition of Viroclinics-DDL is a milestone for Cerba Research, as it enables us to build a comprehensive offering for our customers, with broader capabilities, best-in-class logistics,and key specific expertise that meet the healthcare industry needs. With our combined expertise in immuno-oncology and infectious / respiratory diseases, we are poised to accelerate therapy and vaccine development for biopharma customers while becoming the reference lab for cell and gene therapies of tomorrow. We are very much looking forward to on boarding the team of Viroclinics-DDL and together paving the way for new therapies.”
Viroclinics-DDL CEO Davide Molho added: “With Cerba Research, we have a new foundation for further global expansion to North America, Asia, and Africa with unrivalled expertise, capacity and capabilities. Together, we will be able to offer integrated solutions to the life science industry, accelerating antiviral, vaccine,and other R&D programs,while offering unmatched logistics solutions securing the integrity of fragile samples. Our 390+ scientists and experts look forward to joining Cerba Research in our continuous quest to provide the best possible science and service to our customers.”
The transaction is subject to regulatory approvals and customary conditions, such as completion of the consultation procedure with Central Works Council of Viroclinics-DDL. The acquisition is expected to close by end of Q1 2022.
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine. Every day, on 5 continents, the Group’s 12 000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
About Cerba Research
Cerba Research is a leading healthcare company with end-to-end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization. Providing Early phase research, clinical development through central laboratory and diagnostic services, Assay and biomarker development and validation. Working with government agencies, non-government organizations as well as pharma and biotech organizations to change the shape of clinical development. Cerba Research is part of Cerba HealthCare, a leading player in medical diagnosis.
For more information: www.cerbaresearch.com
Viroclinics-DDL is a leading specialty contract research organization, serving the biopharmaceutical community with a broad range of non-clinical research, clinical diagnostic, assay development, laboratory, and clinical trial logistic services. It offers its clients a global reach through a network of 38 processing laboratories. Viroclinics-DDL extensive experience in clinical and preclinical virology studies, including its specialty in respiratory and blood-borne viruses, puts the company at the forefront in supporting the development of vaccines, antibodies, antiviral compounds,and other therapies. Its in-house state-of-the-art preclinical and clinical BSL-2 and BSL-3 laboratories facilitate complex experiments with highly pathogenic organisms.
Viroclinics-DDL is based in Rotterdam, Rijswijk and Schaijk in the Netherlands, and employs over 390 highly trained, dedicated scientists and technical experts.
For more information, visit www.viroclinics.com and www.ddl.nl.
Cerba Research and ACT Genomics Announce Strategic Joint Venture — CerbACT Asia
Purpose-built facility to enable precision medicine for better patient outcomes
Ghent, Belgium, 08.24.2021 – Cerba Research, a leading global clinical trial laboratory services organization owned by Cerba HealthCare, announced today that they have joined forces with ACT Genomics under a joint venture model to create a purpose-built lab facility in Taiwan covering the Asia Pacific region.
This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
The expansion includes investments in a new facility in Taipei (Taiwan) and state-of-the-art technologies to strengthen capabilities and services offered to our clients on a truly global scale:
- Cutting-edge flow cytometry technologies
- Exploratory as well as In Vitro Diagnostic histopathology services
- Peripheral blood mononuclear cell (PBMC) isolations from blood and soft tissues
Progress on construction, technology transfers, and expansion of the scientific team will enable the CerbACT Asia Laboratory to be fully operational in September 2021.
Mario Papillon, CEO of Cerba Research comments: “This milestone with ACT Genomics validates our innovative history as a company. We will support our customers with the latest instrumentation and automation — backed by experienced scientists whose ambition and agility to meet patients’ needs drive our continuous evolution as a company.”
“We are excited to create a partnership with Cerba Research. Together, we offer a broader range of top-notch technologies and services in Asia. The formation of CerbACT Asia echoes our firm dedication in the well-being of cancer patients, keen commitment to society, and unequivocal embrace of precision medicine,” says Hua Chien Chen, CEO, ACT Genomics.
About Cerba Research: Is a leading healthcare company with end-to-end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization. Providing Early phase research, clinical development through central laboratory and diagnostic services, Assay and biomarker development and validation. Working with government agencies, non-government organisations as well as pharma and biotech organisations to change the shape of clinical development.
Cerba Research is part of Cerba HealthCare, a leading player in medical diagnosis.
For more information: www.cerbaresearch.com
About ACT Genomics: Is an innovation-driven cancer solution provider in Asia with offices in Taipei, Hong Kong, Singapore & Tokyo. With our Next-Generation Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team and proprietary AI algorithms, we provide optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. Together, we “Turn Genomics into Action.”
For more information: www.actgenomics.com
Cerba Research Awarded NIH Contract for Central Lab Services
Ghent, Belgium, 07.27.2021 – Cerba Research today announced it was awarded a five-year contract for Clinical Central Laboratory Services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).
NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. Findings from this research are vital to NIAID’s efforts to advance vaccines, drugs, and diagnostic tools to better diagnose, prevent, and treat infectious diseases. Cerba Research will provide clinical laboratory screening and safety testing for NIAID-supported clinical trials within the infectious disease area.
“We are pleased to be recognised for our depth and breadth of central and speciality lab solutions across the globe to support NIAID. Through our innovative mindset, courageous people, and our work in vaccines and treatments in the field of infectious diseases, we understand the importance in bringing these to people. Hence, we are committed to supporting the NIAID’s clinical research initiatives to improve health,” said Mario Papillon, chief executive officer, Cerba Research.
About Cerba Research: Is a leading healthcare company with end-to-end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization. Providing early phase research, clinical development through central laboratory and diagnostic services, assay and biomarker development and validation. Working with government agencies, non-government organisations as well as pharma and biotech organisations to change the shape of clinical development.
About NIH NIAID: The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. NIAID is composed of 7 research divisions: the Division of AIDS; the Division of Allergy, Immunology, and Transplantation; the Division of Clinical Research; the Division of Extramural Activities; the Division of Intramural Research; the Division of Microbiology and Infectious Diseases; and the Dale and Betty Bumpers Vaccine Research Center. NIAID scientists conduct intramural research in laboratories located in Bethesda, Rockville, and Frederick, Maryland, and in Hamilton, Montana. More information on NIAID programs, committees, and initiatives can be found on NIAID’s web site at www.niaid.nih.gov.
COVID-19: Laboratoire Cerba Ready to Sequence on a Larger Scale
As the leader in NGS sequencing among private players, Cerba has adjusted its organisation to serve the new national objectives and has reduced the time required for complete sequencing of the virus to a third.
Today, with the appearance of variants and very large-scale vaccination, it appears that controlling the epidemic requires a more systematic approach to high-throughput sequencing of the virus, known as NGS (Next Generation Sequencing), in order to obtain a detailed, real-time characterisation of the epidemiology and of the circulation of the virus in France.
Cerba HealthCare, a reference player in medical diagnostics, supports the Health Authorities in their desire to extend NGS sequencing of SARS CoV-2 to private laboratories qualified to identify, monitor and study the variants, in close collaboration with the National Reference Centre (CNR) and Santé Publique France.
Reflecting the mobilisation and flexibility shown by the Group since the beginning of the pandemic, the Cerba teams have reduced the time required for the complete sequencing of the virus to a third and share the results with the CNRs within a week.
With its Cerba reference laboratory and its network of 450 local Cerballiance laboratories, the Group shows historical expertise in specialised biology, an unequalled capacity in the private sector with ten NGS sequencing platforms, and access to a large number of samples representative of the population in the various health regions. These three characteristics have already led Cerba HealthCare to play an important role in the fight against the pandemic. They have also enabled the Group to feed the first Flash studies by providing numerous sequencing data and thus contributing to a better characterisation of the epidemiological data on which the decisions of the Health Authorities are based.
“We are pleased that private players are allowed to continue their participation in the national virus sequencing effort. On the one hand, France has the technical means and expertise to shine in this field, and on the other hand, the scale of the health crisis encourages the mobilisation of all players, both public and private, that are able to contribute,” comments Sylvie Cado, CEO of Cerba. “Cerba is fully mobilised to complement the efforts of the national reference centres in terms of NGS sequencing, with the dual objective of expanding the country’s capacity to curb the epidemic and providing input for epidemiological studies. Sequencing is of course a matter of expertise and equipment, but it is important to emphasise its purpose: to identify and track the spread of new variants allows us to delay as much as possible their circulation within the population, and to hasten the adaptation of diagnostic capacities and possibly the vaccination strategy.”
The sequencing of SARS CoV-2 is in line with the strategy of the Group, which in 2013 was the first private player in France to have a high-throughput sequencing platform. Used in fields as varied as oncology, infectious pathologies and constitutional genetics, expertise in high-throughput sequencing enabled Cerba to develop the non-invasive prenatal diagnosis (NIPD) test in 2013, a genetic test that detects trisomy 21 thanks to the DNA circulating in the maternal blood.
Cerba has been carrying out high-throughput sequencing of the SARS CoV-2 virus since October 2020 as part of its specialty clinical trial biology activity, contributing to various studies dedicated to vaccines or anti-COVID therapeutic approaches.
Cerba Healthcare to Welcome EQT As New Shareholder to Foster Innovation and Continue to Meet the Healthcare Challenges
Cerba HealthCare, leading player in medical diagnosis, together with Partners Group, and the Public Sector Pension Investment Board (“PSP Investments”) have entered into exclusive discussions with EQT Private Equity to enable the Company to pursue its long-term innovation services strategy and enhance services for patients and the medical community.
Cerba Healthcare, headquartered in France and firmly established in Europe and Africa through its historical routine and specialty biology expertise, also operates globally through its clinical trials business unit for the validation of new compounds and vaccines. It stands as a unique group in the diagnosis market, covering the needs for diagnostic tools and expertise for patients, physicians, hospitals and the pharmaceutical industry.
With this new partnership, Cerba HealthCare reinforces its capital structure with its existing shareholders -more than 400 long-time biologists and managers- and its long-term partner, PSP Investments, to sustain the Group’s development strategy and current transformation.
Catherine Courboillet, CEO, Cerba HealthCare, states: “Over the past four years, Partners Group has shown a comprehensive understanding of our market and unwavering support in sustaining Cerba HealthCare’s growth strategy. In order to continue to fulfill the Group’s long-term development, we are excited to welcome a partner that shares the same vision and values, as well as a strong understanding of the importance of cutting-edge, personalized services. It is critical to keep on investing heavily in innovation, IT security and talents in order to drive further and faster our on-going transformation towards better healthcare services for patients. With EQT, we have chosen an experienced partner that will strengthen our European positioning while helping us expand into new markets.”
Nicolas Brugère, Partner, Investment Advisor at EQT Partners and Head of EQT France, comments : “EQT has followed Cerba HealthCare for a long time and we are deeply impressed with the company’s unique platform for medical diagnoses and superior scientific expertise. Cerba HealthCare is a purpose-driven company with a culture that is well-aligned with EQT’s values and we are happy to partner with its management team and with PSP Investments. EQT Private Equity is committed to invest in and future-proof Cerba HealthCare for the long-run to best serve patients and healthcare professionals.”
Kim Nguyen, Partner, Private Equity Services, Partners Group, adds: “Cerba HealthCare operates in an important sector and we are proud to have successfully contributed to the sustainable growth strategy of the Company over the last four years. In line with Partners Group’s focus on positive stakeholder impact and entrepreneurial governance, Cerba HealthCare has not wavered in its commitment to responding to the COVID-19 crisis. During our holding period, the Company has transformed into a market leader, penetrating new international markets, including in Africa and Italy, further consolidating its expertise in clinical trials and securing leadership in the veterinary biology sector. We are convinced Cerba HealthCare is poised for lasting success and that, after our strong and collaborative partnership, it is the right time and opportunity for all stakeholders that the Company move into its next phase of growth.”
Simon Marc, Senior Managing Director and Global Head of Private Equity, PSP Investments, said: “Since our initial partnership with Cerba HealthCare in 2017, the company has gone from strength to strength, and we are excited to continue supporting Catherine and her talented management team as long term-partners. We look forward to welcoming EQT who has been one of PSP Investments core partners for many years, and who brings tremendous expertise in European healthcare. Together, we will provide the long-term strategic capital to support Cerba HealthCare in achieving its full potential through its next phase of development as a European leader in medical diagnostics.”
Following the completion of the deal, which is subject to administrative notifications and regulatory approvals, EQT Private Equity and PSP Investments will work with Cerba HealthCare’s management team, led by CEO Catherine Courboillet, to support the numerous growth opportunities of the business. These include the continuation of the Company’s highly successful M&A strategy on a global scale, as well as the acceleration of organic growth and development in other segments.
About Cerba HealthCare
Cerba HealthCare, a leading player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine. Every day, on 5 continents, the Group’s 8 500 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
About PSP Investments
PSP Investments is one of Canada’s largest pension investment managers with approximately $169.8 billion of net assets as of March 31, 2020. It manages a diversified global portfolio of investments in public financial markets, private equity, real estate, infrastructure, natural resources and private debt. Established in 1999, PSP Investments manages net contributions to the pension funds of the federal Public Service, the Canadian Forces, the Royal Canadian Mounted Police and the Reserve Force. Headquartered in Ottawa, PSP Investments has its principal business office in Montreal and offices in New York, London and Hong Kong. For more information, visit investpsp.com or follow PSP Investments on Twitter and LinkedIn.
About Partners Group
Partners Group is a leading global private markets firm. Since 1996, the firm has invested over USD 145 billion in private equity, private real estate, private debt and private infrastructure on behalf of its clients globally. Partners Group is a committed, responsible investor and aims to create broad stakeholder impact through its active ownership and development of growing businesses, attractive real estate and essential infrastructure. With over USD 109 billion in assets under management as of 31 December 2020, Partners Group serves a broad range of institutional investors, sovereign wealth funds, family offices and private individuals globally. The firm employs more than 1,500 diverse professionals across 20 offices worldwide and has regional headquarters in Baar-Zug, Switzerland; Denver, USA; and Singapore. It has been listed on the SIX Swiss Exchange since 2006 (symbol: PGHN). For more information, please visit www.partnersgroup.com or follow us on LinkedIn or Twitter.
EQT is a purpose-driven global investment organization with more than EUR 84 billion in raised capital and over EUR 52 billion in assets under management across 17 active funds. EQT funds have portfolio companies in Europe, Asia-Pacific and North America with total sales of more than EUR 27 billion and approximately 159,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More info: www.eqtgroup.com or follow EQT on LinkedIn, Twitter, YouTube and Instagram
COVID-19: Institut Imagine and Cerba HealthCare are partnering to test for patients likely to develop severe symptoms
In 2020, researchers at Inserm, Université de Paris, and Assistance Publique–Hôpitaux de Paris (AP- HP), in collaboration with the university hospital organisation Institut Imagine (Hôpital Necker-Enfants malades AP-HP), which has been granted “Institut Carnot” certification through The Rockefeller University and the Howard Hughes Medical Institute in New York, identified the leading genetic and immunological causes responsible for at least 15% of serious forms of Covid-19. Today, this same French and American team, jointly lead by Jean-Laurent Casanova and Laurent Abel* at the Institut Imagine and The Rockefeller University, is joining forces with Cerba HealthCare, a leading stakeholder in medical diagnostics, to transform these discoveries into clinical applications and screen individuals who are more likely to develop a severe form of the disease and tailor their treatment accordingly.
A commonality among 15% of severe cases: impaired type-I interferon activity
At the start of the Covid-19 pandemic, Dr.Jean-Laurent Casanova and his team created an international consortium, Covid Human Genetic Effort, to identify the genetic and immunological factors responsible for the reason some patients experience serious forms of the disease. They focused their research on patients who were hospitalised with severe Covid throughout the world. These patients all had a quantitative or activity-related type-I interferon (type-I IFN) impairment. Type-I interferons are immune system molecules that normally serve a powerful anti-viral function.
In two articles published in the journal Science1,2, researchers discovered changes in genes that were already understood to regulate the immune responses controlled by type-1 IFN, especially in reaction to the flu virus, in 3-4% of patients with a severe form of the disease. These mutations decreased the production of these interferons. In an even more surprising development, they identified an auto-immune reaction in 10-11% of other patients with serious Covid symptoms. These individuals produced autoantibodies that specifically targeted type-1 IFNs. In a recent article published in Journal of Experimental Medicine, these same anti-interferon autoantibodies were also identified as the cause of severe reactions to yellow fever live vaccine in around one- third of patients from an international cohort3, confirming the discoveries of the Imagine teams.
From ground-breaking research to a screening test
“These studies have revealed the crucial role of type-I interferons in the immune response against SARS-Cov- 2 and the development of serious forms of the disease. The genetic variants that decrease their production or the auto-antibodies that neutralise their effect are present before the virus infects the body and play a critical role in the outcome of the disease. Some serious forms of Covid-19 could therefore be prevented by testing the general population to detect any auto-antibodies and by administering interferons at the onset of infection for certain patients”, Jean-Laurent Casanova and Laurent Abel explain.
Against this backdrop, Institut Imagine decided to form a partnership and sign its first collaboration agreement with Cerba HealthCare, a leading stakeholder in the fields of medical diagnostics and specialized biology.
“Cerba HealthCare’s expertise; knowledge of specialised medical biology, from prevention to screening and diagnostics; and its international network are all major assets. This collaboration will help us reach the next level by transforming our improved understanding of the disease into a concrete application designed to help patients. In reality, we are talking about adapting precision genetic medicine to the context of a pandemic”, says Dr. Stanislas Lyonnet, Director of Institut Imagine.
Jérome Sallette, Scientific Director of Cerba HealthCare, adds, “Our partnership with Institut Imagine perfectly embodies our shared vision of the need to discover diagnostic tools and new treatments at a faster pace, particularly by building more bridges between different ecosystems. The reputation, expertise, and commitment of the teams at Institut Imagine are clearly a driver of success in this project, for which we have mobilised all of our areas of expertise. While the epidemic does lead to a race to innovate, it also underscores more than ever the importance of cooperation between public and private stakeholders.”
For additional information, click here.
*Jean-Laurent Casanova oversees genetics and experimental immunology in both branches, while Laurent Abel directs genetics and mathematical epidemiology in both branches.
Qian Zhang et al.
Science, 24 September 2020
Paul Bastard et al.
Science, 24 September 2020
3) Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.
Paul Bastard et al.
Journal of Experimental Medicine, 2021
Europe’s leading hospital and university center, the AP-HP and its 39 hospitals are organized into six university hospital groups (AP-HP.Center-University of Paris ; AP-HP.Sorbonne University ; AP-HP.Nord-University of Paris ; AP-HP.Université Paris Saclay ; AP-HP.Henri Mondor and AP-HP University Hospitals.Paris Seine- Saint-Denis University Hospitals) and are organized around five universities in the Ile-de-France region. Closely linked to major research organizations, the AP-HP has three world-class hospital-university institutes (ICM, ICAN, Imagine) and the largest French healthdata warehouse (EDS). A major player in applied research and innovation in health, AP-HP holds a portfolio of 650 active patents, its clinician-researchers sign nearly 9,000 scientific publications each year and more than 4,000 research projects are currently under development, all promoters combined. In 2020, AP-HP obtained the Institut Carnot label, which rewards the quality of partnership research : the [email protected] offers industrial players solutions in applied and clinical research in the health sector. The AP-HP also created in 2015 the AP-HP Foundation for Research to support biomedical and health research carried out in all of its hospitals. https://www.aphp.fr
About Cerba Healthcare
Cerba HealthCare, a leading player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine. Every day, the Group’s 8 500 employees through its subsidiaries on 5 continents sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Inserm is a public scientific and technological establishment, under the dual supervision of the Ministry of Health and the Ministry of Research. Dedicated to medical biological research and human health, it is positioned along the entire path from the research laboratory to the patient’s bed. On the international scene, it is the partner of the largest institutions involved in the challenges and scientific progress of these fields.
About Institut Imagine
In an architecture designed by Bernard Valéro and Jean Nouvel on the campus of Hôpital Necker-Enfants malades (AP-HP), Institut Imagine, which has been labelled Institut Carnot, is the leading center for research, care and teaching on genetic diseases. With the mission of understanding and curing these diseases, the Institute brings together 1,000 of the best doctors, researchers and healthcare personnel in an architecture that creates synergies. This unprecedented continuum of expertise, combined with proximity to patients, enables Imagine to make discoveries for the benefit of patients. The 7,000 or so genetic diseases identified affect 35 million patients in Europe, and nearly 3 million in France, where there are 30,000 new cases each year. Nearly 60% of the children seen in consultations leave without a genetic diagnosis and 90% of genetic diseases do not yet have a cure. Faced with this major public health problem, the challenge is twofold: to diagnose and to cure. www.institutimagine.org/fr
About Université de Paris
As a research-intensive, multidisciplinary university, the University of Paris ranks among the most prestigious French and international institutions thanks to its high-level research, its excellent higher education programs, its support for innovation and its active participation in the construction of the European research and education area.
The University of Paris has 61,000 students, 4,500 professors and researchers, 22 doctoral schools and 142 research laboratories. Visit u-paris.fr.
A New Paradigm for Patient Recruitment: Leveraging Medical Laboratory Data for Patient Recruitment
Ghent, Belgium; February 15, 2021 – Cerba Research, a leading healthcare diagnostic company and wholly owned subsidiary of Cerba Healthcare, today announced a new partnership with Biokortex, a provider of digital solutions to the healthcare sector. This partnership will leverage patient biological and medical data to support drug developers and CROs with patient identification and recruitment activity.
“Cerba Healthcare and Cerba Research are committed to investing in technologies that will reduce the patient burden of participating in clinical trials and help our clients to accelerate their development strategy. Biokortex will allow them to prospectively identify potential patients and offer them a safer alternative to access innovative treatments,” said Mario Papillon, CEO at Cerba Research.
“Digitization is providing an impetus to move away from centralized, high-cost, and difficult-to-access settings to more virtual, patient-centric, and efficient clinical trials models. Cerba Healthcare is the perfect partner to build the future patient’s care path,” said Biokortex CEO Adrien Ko.
The benefits of this new partnership include:
- Leveraging patients’ biological and medical data — as well as biomarker and genetic data from the Cerba Healthcare network — which comprises over 25 million patients per year from over 1,000 sites located in Europe, Africa, and North America
- A global footprint with data on global testing, frequency, and accuracy
- A platform for screening and companion diagnostic testing across Europe and Africa
- By connecting real-world laboratory data from clinical sites and digitizing patient data, this partnership will optimize patient recruitment for precision medicine by identifying patients expected to respond to your product — moving efficiently into clinical trials and allowing patients to receive information on new therapies at the right time
About Cerba Research: Is a leading healthcare diagnostic company with end to end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization. Providing global clinical trial central laboratory solutions (speciality lab, FCM, ICH, NGS, BioA, metabolomics), translational science (biomarkers development, CDx, biobanking), and IVD (biospecimens, prospective sample collection, IVD evaluation).
About Cerba Healthcare: The parent company of Cerba Research is an international network of medical, biological laboratories operating in private and public sectors. Providing doctors, medical biology test laboratories, and pharmaceutical companies a comprehensive offer in terms of biological diagnosis from the local laboratory to the hyperspecialized biology laboratory.
About Biokortex: Provides IT solutions for process improvement in medical research. Connecting the players of the medical world and bringing digital solutions to current unmet needs. Biokortex is the result of the founding team’s experience and numerous interactions with stakeholders about collaborative work organization and the digitization of medicine. Biokortex is positioned as a key advising company in digital strategy for medicine and its industrialized forms.
Cerba Research Announces Time-Saving COVID-19 Exploratory Tools and NGS Advancements
- Enhance viral load measurement for SARS-CoV-2 using digital droplet PCR
- Enable whole-genome sequencing in NGS of the SARS-CoV-2 and other respiratory viruses
Cerba Research announces today that it has developed two new COVID-19 exploratory tools to enhance clinical research for the development of vaccines and treatments for COVID-19 and other infectious diseases. Developed by scientists at Cerba Healthcare on nasopharyngeal ongoing patient samples, these tools are available and efficient on clinical specimens. Furthermore, this whole-genome sequencing in NGS assay is available for other viruses responsible for respiratory diseases like influenza viruses.
The developments reinforce Cerba Healthcare and Cerba Research’s scientific commitment to the continued fight against the pandemic. Cerba Research recently announced its In Vitro Diagnostic (IVD) division supported The French Public Health Agency (Santé Publique France) in a prospective COVID-19 seroprevalence study now identified as a major partner for epidemiological studies with the French Government.
“Since the onset of the pandemic, Cerba Healthcare has been at the forefront of fighting against COVID-19 with all stakeholders, including patients, healthcare professionals, governments, IVD professionals, and pharmaceutical and biotechnology companies developing vaccines and treatments. Our new COVID-19 exploratory tools help our clinical research customers develop more tailored and effective treatments,” said Jérôme Sallette, chief scientific officer at Cerba Research.
Viral load measurement for SARS-CoV-2 using digital droplet PCR
- Use in treatment and vaccine trials
- An innovative method enabling SARS CoV-2 absolute quantification
- Increased sensitivity and precision as compared to qPCR assays, especially in low viral abundance samples
- Follow-up of patients with low viral load
- Accurate assessment in viral load variation
- Performed in an ISO15189 accredited lab
Whole-genome sequencing in NGS of the SARS-CoV-2 and other respiratory viruses
- Use in treatment and vaccine trials
- Viral determination and subtyping (SARS CoV-2, influenza, RSV, adenovirus, pneumovirus, rhinovirus)
- Detection of virus mutations
- Assessment of viral heterogeneity and quasispecies
- Precise detection of co-infections (e.g., influenza subtype)
- Documentation of proven reinfections
- Can be combined to host genetics to address individual genetic susceptibility to infection, level of the immune response, or severity prognosis factors
Cerba Research Becomes Latest Partner of One Nucleus
Cerba Research has become the latest Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs both of the Partner and the interests of One Nucleus members.
Sofie Vandevyver, Head of Business Operations & Marketing, Cerba Research declared ‘we are proud of having formed this exciting new alliance with One Nucleus. We are confident this collaboration will allow us to bring people together and drive our leadership position within the field of precision medicine.’
Tony Jones, CEO of One Nucleus expands further ‘One Nucleus is committed to connecting the life science community and showcasing the expertise of our members that will support other businesses in the sector. We are excited to welcome Cerba Research as our newest partner and it is only by building these relationships that we can bring valuable insights into our network to drive the discussion that will move healthcare innovations forward.’
About Cerba Research
Cerba Research provides the highest quality specialized laboratory and diagnostic solutions while leveraging patient data and scientific insight to shape and advance clinical trials. With our global footprint and access to leading regional labs, data, patients, technology, and partnered resources, we support global biotech, pharma, and IVD organizations to improve the lives of patients around the world.
From the translation of preclinical to clinical, through commercialization, our expert scientists collaborate with you to optimize your therapeutic development and obtain critical insights earlier. We help accelerate your therapies through the development of highly specialized custom assays, deep biomarker expertise, and a passion for scientific innovation across complex therapeutic areas. Our global network of leading, specialty laboratories ensures you have access to quality data and can reach your patients. Together, we’ll improve patients’ lives around the globe.
About One Nucleus
Established in 1997, One Nucleus is an award winning not-for-profit Life Sciences & Healthcare membership organisation centred on the Greater London-Cambridge-East of England corridor. Headquartered in Cambridge, at the heart of Europe’s largest Life Sciences & Healthcare cluster, we support those institutions, companies and individuals undertaking activity in or with the above region.
Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximise their performance. This support helping them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.
For further information, please contact:
Tony Jones, CEO
Email: [email protected]
Tel: +44 (0)1223 896463